<SEC-DOCUMENT>0001613103-16-000113.txt : 20161228
<SEC-HEADER>0001613103-16-000113.hdr.sgml : 20161228
<ACCEPTANCE-DATETIME>20161114173509
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001613103-16-000113
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20161114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medtronic plc
		CENTRAL INDEX KEY:			0001613103
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0424

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		20 ON HATCH, LOWER HATCH STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2
		BUSINESS PHONE:		01135314381700

	MAIL ADDRESS:	
		STREET 1:		20 ON HATCH, LOWER HATCH STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Ltd
		DATE OF NAME CHANGE:	20150112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Holdings Ltd
		DATE OF NAME CHANGE:	20140711

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kalani I Ltd
		DATE OF NAME CHANGE:	20140709
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s88acdd4dd8d5453aacace338d917b9b5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;"><img src="image1.gif" alt="image1.gif" style="height:33px;width:204px;"></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Medtronic plc</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#163767;">20 On Hatch</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#163767;">Lower Hatch Street</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#163767;">Dublin, Ireland</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#163767;">www.medtronic.com </font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">November 14, 2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Via EDGAR Correspondence</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mr. Martin James</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">United States Securities and Exchange Commission</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">100 F Street, NE</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mail Stop 3030</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Washington, DC 20549</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Re:&#160;&#160;&#160;&#160;Medtronic plc</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Form 10-K for the Fiscal Year Ended April 29, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Filed June 28, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Form 8-K dated August 25, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Filed August 25, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">File No. 001-36820</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dear Mr. James:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Please find below Medtronic plc&#8217;s (&#8220;Medtronic&#8221; or the &#8220;Company&#8221;) response to your comment as noted in your letter to the Company dated October 31, 2016. For ease of review, we have included the comment from your letter in </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">italics </font><font style="font-family:inherit;font-size:12pt;">and included our response in bold font below the comment. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">Form 8-K Filed August 25, 2016</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">We note your response to comment 3. While you do not describe your restructuring charges as non-recurring or in other terms that mischaracterize the frequency of these charges we note that you have incurred restructuring charges in each of the last three years. Please explain to us in detail your restructuring plans for each of the last three years and explain to us why these are not normal, recurring, cash operating expenses necessary to operate your business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Medtronic Response:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">As a point of clarification, we believe the Staff intends to refer to comment 4 from the September 22, 2016 letter. As indicated in our October 6, 2016 response, we do not view restructuring charges as normal, recurring cash operating expenses necessary to the operation of our business. We incur restructuring charges in connection with our cost-reduction and productivity initiatives or with acquisitions when we implement plans to restructure and integrate the acquired operations. During the last three fiscal years, our restructuring charges consisted of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;text-decoration:underline;">Restructuring Charges Incurred in the First Quarter of Fiscal Year 2014 through the First Quarter of Fiscal Year 2015</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">: </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">During fiscal year 2014, net restructuring charges for Medtronic, Inc. (our predecessor registrant) were $88 million.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">In the first quarter of fiscal year 2014, Medtronic, Inc. recognized restructuring charges primarily related to distributor and agent contract termination costs associated with a shift in selling strategy to sell directly to the consumer in Latin America. The restructuring charges also included remaining lease payments related to office optimization efforts associated with the first phase of a strategic shift in Europe to reduce back-office support functions, which was part of the  &#8220;Fit for Growth&#8221; initiative designed to scale back infrastructure in slower growing regions of the business. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">In the fourth quarter of fiscal year 2014, Medtronic, Inc. recognized restructuring charges related  primarily to employee termination costs and asset write-downs as a result of the second phase of the &#8220;Fit for Growth&#8221; initiative and non-cash fixed asset and inventory impairment costs associated with discontinued product lines. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">In the first quarter of fiscal year 2015, we recognized net restructuring charges of $30 million, which consisted primarily of distributor and agent contract termination costs associated with a shift in selling strategy to sell directly to the consumer in Europe. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;text-decoration:underline;">Restructuring Charges Incurred in theFourth Quarter of Fiscal Year 2015 through the First Quarter of Fiscal Year 2017:</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">During the fourth quarter of fiscal year 2015, the Company completed the acquisition (Acquisition) of Covidien plc (Covidien) in a cash and stock transaction valued at approximately $50 billion. In connection with the transaction, Medtronic, Inc. and Covidien were combined under and became subsidiaries of Medtronic plc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">We began our restructuring program related to the Acquisition, the &#8220;Cost Synergies&#8221; initiative, in the fourth quarter of fiscal year 2015. In the fourth quarter of fiscal year 2015, throughout fiscal year 2016, and in the first quarter of fiscal year 2017, the Company recognized net restructuring charges of $222 million, $299 million, and $104 million, respectively. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">The &#8220;Cost Synergies&#8221; initiative includes restructuring charges related to the integration of Covidien, including costs associated with duplicate facilities, manufacturing and supply chain infrastructure efficiencies, certain program cancellations and general and administrative redundancies, multiple distributors in the same region, and a shift in selling strategy to sell directly to the consumer, as opposed to utilizing external distributors within our sales process. Restructuring charges primarily related to employee termination costs and costs related to manufacturing/building site closures.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">We are in the business of providing medical technology, services and solutions to further the provision of healthcare across the world. Our restructuring expenses relate to ancillary cost-reduction and productivity initiatives, such as severance charges arising from the reduction of excess overhead, which are not considered normal to operate our business.  The restructuring programs described above affect comparability of our operational results. The expenses do not reflect investments in our current operations and are not indicative of performance by our current operations, which are the focus of both management and the investing community when evaluating </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">our performance. Restructuring charges are not necessary to operate the business and are not necessary to generate revenue. Additionally, the restructuring charges included in our non-GAAP adjustments are expenses incurred by the Company with no related benefit to the Company&#8217;s current operations. As such, including restructuring charges in the determination of operating margins would result in providing confusing information to the users of the financial statements about a particular period&#8217;s operating performance. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Moreover, the nature, frequency and magnitude of restructuring charges do not recur predictably from period to period because our restructuring programs may be impacted by acquisition activity. This is illustrated by the variation in the level of restructuring costs from fiscal year 2014 to the two years immediately following the Acquisition, and by the fact that our restructuring expenses in fiscal years 2015 and 2016 primarily derived from the Acquisition. The Acquisition was a significant transaction for the Company. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">In light of the foregoing factors, our management uses financial measures that exclude restructuring charges to facilitate reviews of operational performance and as a basis for strategic planning, and management believes that such measures allow investors to supplement their understanding of our short-term and long-term financial trends. We do not believe that it is misleading to exclude the impact of restructuring charges from clearly-labeled non-GAAP financial measures, because our restructuring charges are not normal, recurring operating expenses necessary to the operation of the business. The adjusted figures are expected and requested by our investors in order to quantify the impact of our restructuring programs and facilitate their review and understanding of the results of our operations.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you have any questions regarding these matters, please contact me at (763) 505-3070.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sincerely,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Karen L. Parkhill</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Karen L. Parkhill</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Executive Vice President and</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chief Financial Officer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">cc:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Bradley E. Lerman</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Senior Vice President, General</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Counsel and Corporate Secretary</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Martha Ha</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Assistant Corporate Secretary</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image1.gif
<TEXT>
begin 644 image1.gif
M1TE&.#EA(P<L ?<           $! 0!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+
MAP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+
MAP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+
MAP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+
MAP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+
MAP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+
MAP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP!+AP%+AP)+A@1,
MA0A-A ]/@AE2?R=6>SA:=DM@<5QF;6MK:VQL;&UM;6YN;F]O;W!P<'%Q<7)R
M<G-S<W1T='5U=79V=G=W=WAX>'EY>7IZ>GM[>WQ\?'U]?7Y^?G]_?X" @(&!
M@8*"@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0
MD)&1D9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYR<G)V=G9Z>GI^?
MGZ&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^
MOK^_O\# P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-
MS<[.SL_/S]#0T-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<
MW-W=W=[>WM_?W^'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOKZ^SL
M[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ^OO[
M^_S\_/W]_?[^_O_______R'Y! $     +      C!RP!0 C^  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;+&?HW,FSITZ<0(,*;>BSJ-&C2),J7;IT:$BF4*-*G8K4J=6K
M6+-J54FU*]2M8,.*'4NVK-FS:-,R],KVI]JW8MO*G=L5;D*Z>/,FM<NWK]^_
M"/7.!4RXL.'#B!,KYBL8[^+'3QM+%OQWLN6\D#-KW@SR,E7.H$.+'DVZM%G/
M=$VK)HBZ-5N[KF-/74V[=F+938'B5FJ[M^_?P'OOKAN<\_#C1]\B7^ZSN//G
M6)DWURV=)_3KV+-K#UM][W;$W:O^GPTO_;OY\R7)SPBJ'KW[]_#C<R0OG[#Z
M\G'O,Z_/O_]=^M2%Y]^ !!8(GVL&5J8??EDMR&""$)K77H#=16CAA1AFJ.%8
M%0HTH54= @#@AB0*-^)-'Y:HXHHLMNCB1 (.E"*%^\EX8FD/OKC0;ES=6-.,
M.A[TF68Y!MDC@D::6..110(Y4XRL^0B7@TAN1R5F%%VIY9959BF>15\.Q65K
MAH58T9A2C>?D8FAZ%A&4!JW9$IP%R0EBFPZ"AN=Q_^WIYY^YG1GFCGF^!&BA
M99FIT*&4774?8(P66:>B<4K)I*0VTHE3I'_VQ6E[GX;JYT64>CAF>J(>&MV@
MF:9ZV:;^=FKEJJ91EEJIK2?1.JFE<\X:*EB^!BOLL(.!&6:G\Q'K*JSX*2N;
M3(_*ZJRNIK*Z**\B47LKKJA..RNSWH8K[K2DCMNHE^8.&U.ZX?:*[9/L6MLJ
MIGURVY&V0L9Z+Y[KGNKNJ"X%R]Z[P,:;&D21KI2PPK\RW&9*T?[8<, 'YRLO
M4027>_%:&6N\8*+ZF>0O=\B"NW%^GP[,)8<CD\3OJHBZK&^N:/I55&#X$IHS
MNDO".+///Y,5])M4*KBERO867'.#14/:=+97IO7Q2!'GI*5I'5^;--'T(IRU
M0T,KM_5#,1_V-(I?.QJUTE4K5G:R(3,6MD1MTSQU;3N#G;?^SEU[G7:]?9M]
MLMYS>UHW386+&3?)B1O]-\:/,SXVSY-O=+>2@].]][8]8W2XYIG?%CK.C3L>
M.,6;JQTYO*7;][F@J8,<.]FM<[TZD973GOKL'-\NHL' >P<Z[X41WVWN=QK?
MK^^",U\K\D([3[KR?DOO-O6 =ZZU]I:7'OSWR0T//7BC6XV]3=:;?W[QKXM_
MNM3I[[I^[_.+7C[L@X]?O?[@]]\3T/6#S?TN]3ZFZ0]:M2.?]1)HP /RS8'[
M&V!HXI<]Y%201\?CG_\V2#D)-J^ #H,@VD1H* :Z+GTF5!T)+1; "R['.13<
M7N<\:*S5;;!_^&NAFE;XD12RCH;^$HOAE'SH0Z<4<5Y !* .;;9$&;[P=T^$
MF/>::*#%;:9],#EB%JEH-RW*KHA>I!$(;<=#R(5QB&6,H+G^Y< S#NAM'W1C
M#=.XO"2B[W*/@6-&Y!A$.E:+B]/C(\O\J+LUH@Y[5DP2YP2YQ:N)D7O1(^0A
M$\E$/78/D'VTHQ/'N*^S&0>3#W16'=?G2.#P1F1'B^2>'JE)Q($RA&O[HB>A
M]DH$+A&+72RET]PBQ X*[(=T!%@E]4+ EHTR52:C),Q:F;Q5VM*94JSE,2&I
M$4M&4U7)C,H?.2FS7[KRC#=,V23#24ZC=(:#<^2F+,LI3#:J$V62A**P]LA.
M,C%2C0O^&Z$TZVG,$O*SG%0#G\?>";]_XA*6!&4;,T.)S!X:U#&]K*8X64E-
ME#Q4FF2\J/ 6V<Z QFN@%86,1LEDQ(AF,XJH;&A*1_HRH3"JF?'T'$M?);EZ
MIG-I"%462%%JFYE^99 QO2-&D5@R?_K4I'"#IN+NZ="CKB<SX[HF'I^I4E]:
M\#SAW&50,YG0<^)TJ3=4I%C76=3^*+.F)%5E+,>*-%VR]:T9Q. PW=I-=;%)
MIW#-J]R&JM>^^O6O0&T,8"GJ*P6*<K"(W0I3$\O8QCJVKB%];%.]=4+*2O:R
M7(TL9C?+V<[2<JJ>E:DA!3C:T)H6LET]K6I7V]F5L3:'417^6[I>2]M+;M6J
M5ZVM;G=+VK7REJ&QW>%'?TM<,RYTLL<MKG*7FTND2E:@:ATN<Z>[S=1&AJ_4
MS:YVC8N;[0)7NM+"H7>+N]A")G>\Z$VO:-NBWHQ:L+RP?:]SVYLD^')7L_3-
MKW[W"U.4SI>>Q_HO?U=D7_J==\ (3K"" 9RC AN8IPYN9#X35-;U.G6V-^53
M)V-#5FSBSKKR2V5O;QM=3B65IT1%\30U'.(#&Y6<F&.7>2\<7-QVU[WXM>A#
M]YKC%-M5L1%6GTTWR6(6NEB)*O9QD?M+8^O$\:(M;K)EXSL<(A]TPU*NBD)S
M:^2PMO7($G;J=^7JPB7GU,Q1[K'^CK/\FM.P^<TRSG"5G]=/V\)9+F#UKYB!
M">:XPMG*9!YSH-?\O@C?V3),/K2B#TME'GE8SHL6[#<CC69"D]C"E'9+().\
M:35CFLL/!C$^.XKD"@M95)#.-)13;=!2JYK#XYRGC5MJZ3[O]-4[*?.@0\WI
M$_>ZTYZ>-79QO,^'Y1E07P[VL7^,:<(9.]F^]?-7)SW+SUZ:UZX-;Z X6NG[
M_IK5SQ+VKB5ZUA(K>]3#]FJ=^7QN:*];J-%V<[61.V\57OG6WY9VN>_:QA;V
MFX+W1@O K8E&@K]8U.P&[;+3[<Z(UCNP,0TXEO?]268N4(02!_2<16IQBE=6
MP.YK-V'^$2Y5AE-;AQZ7=Q,SSN @+U/4OB-E D&>Z'$[V^3PMC6X;UQ0FD]<
MY_ ,(,O12G(E=UO=. ?R@1\G]-;YO.8\)W:^KW=M=&]<X$^W<]6W?%R7-U?D
M&K\Z:HO./C^FS>Q3Q#6M9PSTH$_]U&#7)]F_/O>"\]#K*SWRT%W]=M(X?&?Q
MW+O:E<KVN)L.U)GMN[T-WW#&EUWF2<_[W/<><L<;MNY&CSJW-8]T( Y^[3=O
M.\2/'F;,PQWQ#8S\PA4O:)N/>/*"I#Q404FKMJ>\RY]_>.M=_V'3[SS</?>]
M1[.N[?GA7=^D_SWPQRY\V8J^NEQN?N9Y'_;<V_'V3[;\SUG^7]*M;U_[SJ_?
M\9F/>G+7$OL5?_[T[2G]]2^?[V+/J\(OKWHZMU_RW#_I_;M_Q/$/7^],97!7
M-&P&$VM@)WL:HGNOYW_0EW\N57_XMG\GMW+$=WKEUW+JYW[QIR?IAF$&Z(";
M!WX#F&OD!X$8&&\)!X+ZMX$J-W\MB'Z-EGQJX44(^&DP:#C>EV;>5'H(]VYY
M1!SXIX")1W@3F(.^IH+\EVU0=X,1R((\!H N1VI$]S_R)(&Z-E%4!6:HYFYI
M57*/]GU3MF)"F$Y-R'DXN(4G.&%>B(3%5W=*:($38X.-4H' 9F)R!W36-QE9
MF(=?>(0%J'Q=2']\R%Y[R(:I9WK^Q.*'F5:%(FA^=KB",MAY@Y@F=WAG.@AZ
M].:!X@9KZ3>)X0.)U#>#_[6#F6B)=(AMSS9RD4AWGNAD2_A/A>>#DD@N@(@:
M>/-Y2F>$9W:!UJ:&K-B*;9:$F%B)C7A=E#97P>,1J?B!505_H4@;/A5^5MAX
MO%AKRYB"P/B)POB&#\B :1AGOQ&'V+B*!V=J5F>&[T&+5*>+Q62()9B!8/@M
M6E=8_,9L"Q9:WGB/^KB/V^@5_'B)S?AX]OB/EY6/!'F0"/F+DJ9@[9)]LI:0
MCV60$#F1%%F+DH%@XE(F#5F1B261'/F1(!F"Y+A<-8:,B1B2@.61*+F2$SF&
M))F16J7^CBPI?Z<XDS89DG2U79JX@(QVDV.EDCX9E /&C=H%CG:WD4)97S69
ME$RIC[+XDCN)=5'9E"WBC4!)E5C9B0)(7N E7*65E2QBE4L)EF2)-3E9E'_H
ME5-9EADBEB;(EG#)<5O)E<"CEFL9EQ'BENR(EWRIE? X6- U>G?9EP6BEW])
MF(C)@=,(F($YA5^9F%4TEB+YC)!9F5A%F6CY/8)IE);Y1I()D)C9F:+Y'7IX
MC^B4BYHYFI[YEE>IFJ[YA.;4DJ?Y<JGYFO5AF(MIF[JYFXNG85<9(Y_)FT=9
MC'(XDL)YG,C)DW*EDE#2FLG9F^Y8BM7XG-19G2\8?<$YF9S^R(C$*8@;55N4
M.(3&:8W1*9I#\H_:9)V[1X5<J'GY2"?.^7\HF( N^(W9Z))UB([S2$S#.9^S
MAXCQ&8/C.8)/68;;V8#328V#%J 6:8X2@H8->I\B1T+E&82DJ)$@YHL=5J%2
MV9/.^'X(.J#O"*(U"(HE:4HP>8X2ZG0TE)TA6I<FZ82H*(ZH>9CCF);5UR6@
M":)B.&X,:G^PB".SF9\K*GN54Y_DN6/!EZ :2(^TF9MK.&17>*! RJ$1>I%$
M&IHW.E+_&:0[6J3_%EEGB7PT9F[4EU6KQZ2.N6I3JJ-?2J4*JI_<::6S^&<Q
M.5--"J9JFJ5NFJ=[6IR+5J.5IJ3^Q$BG<<I2ZQF(VLFC[2BC<VJH@'J,HJBG
ME+J0FVB+;TI%]_F*.AJ-XBFB12AE.=JGF:JH47JFQR>AFUFIK(IG5WHNC^J?
M MJ*[<F)3;:E<MJ-D3:JIKJH<&JAH5BB]@F,3]JJQEHLLXHDR.:(QYIS\L5F
M/-B=RHAKO.HFH2>MOHJIWO:GTJFGM7JLX'J>EPI0!MJJN!JN) B'H)JDDLJG
MI.JNOVJ,/2:L4F>NGXJN^)J>R2JEE9>OKGBH_IJNI[JN(]JNN#>2C+0Y]+JM
M1%FGLDJFT^:P$.JLV#JP7AJ+RZJ(#EJP&SNL#SNMV3F0D8JLV:JM&*NE^]JK
M;<JHW;K^L!H[5%(8K1E;J 1+LZUVLA^KD/BYG\.XBRZ;J/$*L&-:B-M6JC35
MKX[*K-P:JTGKL5 ZKKD:CS\KGSW;HTW;AC0JLW-YKB06L_=J>UY'A*OZ5 =[
MM65KME![M/6*LBJZM-_*MFW[M$[+A#H;M8(JME^[ETI+MT@[M1 +J7YJK5KK
MMP&RLB;;MW:;MHBFN((+LB[*LS5KN)%KHJSYN"D+E"+6G\[5L%BK<X1[K7P;
MHZ#:?P?TLY]+L6X+M&AKIH_[H_!JHXP;M)K;9SE[B+9VNM6ZNO9S??&C/"[K
MNI=[N.4ZN;;;NI8;NRRKJ[C[MKH;MW#;C\2YO&<KM]#[O('^N[ASJ[+.J[T?
MFKP?9XA;.[L5V[W>RW7'*[GE^[TH%[J<FKC!R[T2.[[7&;DS1Z$F=+[ ZK[H
M^Z[>*;]KJ[_0";NOJK8$&D/L&\"IR[#$"[H"W+F36SLK5*+X6[?PJ[JRV[\)
MS+$7?+?^*[4+W*$#-\'9R[\C"\ E;+WU"'.^VW7UJ[>A:L)5VL'5V[P4O,$.
MG,&#^\'2F%S ^[_IB[RE6<,_/!J]2SQI!,%O68YP>\"P";@#;*EVZ<14*\,<
MC,-&V[AWVHC2R[0Z+) <RG1+QZ(!B[T^/,3K2,4*C,(VJ\;,:,59K,))W+)L
M/+TT3+XP[)=N7+)8/*,VC+C/.\;^>YS&=:R^7;RW>?S"@VRUB>R0T=G#VRN\
MD%O(>@S),:;%>T-(E ?(!,S A]S$B]R+:"ROH7S"9MRE=R?"AES(TKO%XGO'
MG/R,6IAVF@S%K_S)AR?)I%S!-SS'ZFK+& IY+IR_O'S%@1R_PXS!KHRS&QQX
MC3/+0?S(E#Q!#?RZNER\N*S!?8S'[NC(RES*T%S,<GS,O^Q[^!)QS>S,M"S(
MR>S%U_S$L!K%[0S*H[S+#XS*(US-?KS.W[S)E2S%U!)4@H?.[US+OJR<XAS)
M!ZW$\2S/4@S/A\S-!.W-W2S10(REP3%?EH*'YRS0CE'1Z:R8U#O)_,RZ"2W$
M)"S-*&3^S[D<S2O-TAY<TJ);T!:\R:(W=!R-)79,T6^\T#F-SP@,TW\+U []
MT"H]O"?]OB[]TCIMR@W]HN_W? %]TX2(U. LE\%,S&0\U/JLR#+=RC(-T>J<
MS64LUD9-UKUW?\V)UK(LU>+:TT?-R)VLU&]MS5W=RW4-PD=<U.[,G^&\U?M<
MU42,40*2@9D<QQ?-Q%I]UZFLV&WLUUPMU.8+?F#-QXXMTB/-T/-<K#P=PREJ
ML8,\V4Q]U3Z;V=2<U%4,V<*\V6EJI:"=NX"]UWS-KJ2]VI4]UA<JVXG,RO$1
MODMJO(:=SW/=OHS]TW3:VOM[V2W]VL8<UY-JHUW9J#B,V!?^LK,D+=K7^\R)
M;=;*J]M$&\N__;()S=W7[=/LS-RV/;&C;<M(^B)#.[_2W==+3;G!K=G?7=9
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M"01 %K2^]D/!J&O!"KR]_/,_XWO!C3,_N1I!!2Q!$WR]#XQ %?S!_?,^6VO
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E;7,[ ?&#9XYTI_=YEW@QX?2J"71MF>_$&?>+!WGGM667" @ .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
